➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Mallinckrodt
McKinsey
Moodys
Johnson and Johnson

Last Updated: July 31, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOBELINE


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Lobeline

Trial ID Title Status Sponsor Phase Summary
NCT00100074 ↗ To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Unknown status National Institute on Drug Abuse (NIDA) Phase 1 To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
NCT00439504 ↗ Ph1 Lobeline Interaction Study - 1 Unknown status National Institute on Drug Abuse (NIDA) Phase 1 The purpose of this study is to determine if there are significant cardiovascular or other interactions between sublingual lobeline and intravenous methamphetamine.
NCT00519259 ↗ Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1 Unknown status National Institute on Drug Abuse (NIDA) Phase 1 The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.
NCT00664703 ↗ Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients Completed National Institute of Mental Health (NIMH) Phase 2 The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
NCT00664703 ↗ Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients Completed Yaupon Therapeutics Phase 2 The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.
NCT03299452 ↗ Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor Recruiting Haining Health-Coming Biotech Co., Ltd. Phase 2 This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS,safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on the accelerated PDX model screening in subjects with advanced malignant tumor.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Lobeline

Condition Name

Condition Name for
Intervention Trials
Methamphetamine Dependence 2
Attention Deficit Disorder With Hyperactivity 1
Amphetamine-Related Disorders 1
Metastatic Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Neoplasm Metastasis 1
Attention Deficit Disorder with Hyperactivity 1
Amphetamine-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lobeline

Trials by Country

Trials by Country for
Location Trials
United States 4
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 3
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lobeline

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Unknown status 3
Completed 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lobeline

Sponsor Name

Sponsor Name for
Sponsor Trials
National Institute on Drug Abuse (NIDA) 3
Haining Health-Coming Biotech Co., Ltd. 1
Yaupon Therapeutics 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
NIH 4
Industry 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Boehringer Ingelheim
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.